Dr. Reddy's Laboratories Ltd. expands further into consumer health with a £500m ($632m) agreement to acquire rights to OTC nicotine replacement therapy products Haleon plc markets outside the US.
The Indian pharma giant gains rights to a global portfolio of OTC NRT brands marketed outside the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?